KNSA · Kiniksa Pharmaceuticals International, plc
$76.75
-1.08 (-1.39%)
At close · Aug 14
Market Cap
$11.98B
Shares
156.05M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$76.75
Open$77.32
Day$75.30–77.51
52W close$33.04–80.92
Avg vol 30d681K
Short int4.3M · 2.8% float · 5.0d
Short vol47%
Last earningsJul 28, 2026
DataJan 2020–Aug 2026
Filing10-Q · Jul 28
Up next
Next earnings call
Oct 27, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 28, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+54%
above
Price vs 50-day avg
+20%
above
RSI (14)
62
neutral
MACD trend
Negative
52-week position
91%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+20%
trailing
6-month return
+62%
trailing
YTD return
+86%
this year
Relative strength
+48%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $64 › 200d $50 — 50d above 200d
Institutional flow
Accumulating
+15% holders QoQ · +71 funds added
Insider flow
Distributing
Net -$299.1K over 90 days · 100% sells
Short interest
Falling
2.77% of float · ▼ -4.3% MoM · 5.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
265 holders — near 2-yr high, broad support
Squeeze score
55
elevated · 0–100
Fundamentals
Revenue growth
+60%
Y/Y
EPS growth
+225%
Y/Y
Free cash flow
$136.4M
Valuation
P/E 84.3
rich
Balance sheet
$165.6M
net cash
Quant / Vol
risk profile
Volatility
50%
annualized · 1-yr
Max drawdown
−21%
past year
ATR
4.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 28, 2026
ARCALYST net product revenue
· 2026
$980M – $995M
Prior guidance
period ended
· from the Earnings Call filed Sep 30, 2025
ARCALYST net sales
· full year 2025
$670M – $675M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+54%
Bullish
Price vs 50-day avg
+20%
Bullish
RSI (14)
62
Neutral
MACD trend
Negative
Bearish
52-week position
91%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $64 › 200d $50 — 50d above 200d
Institutional flow
Accumulating
+15% holders QoQ · +71 funds added
Insider flow
Distributing
Net -$299.1K over 90 days · 100% sells
Short interest
Falling
2.77% of float · ▼ -4.3% MoM · 5.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
265 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $33
Now $77 · 91%
Range high $81
vs 200-day avg +54%
vs 50-day avg +20%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Approximate share of multiple recurrence population actively on ARCALYST therapy | 21% | second quarter of 2026 | — |
|
|
|||
| ARCALYST net product revenue | $243.6M | second quarter of 2026 | +55.4% |
|
|
|||
| Average total duration of ARCALYST therapy in recurrent pericarditis | 3 | second quarter of 2026 | — |
| Number of multiple-recurrence patients | 14,000 | second quarter of 2026 | — |
|
|
|||
| Prescribers who have written ARCALYST prescriptions for recurrent pericarditis since launch | 5,000 | since launch, as of second quarter of 2026 | — |
| Cash balance increase in 2025 | $170.4M | the full year 2025 | — |
| Gross-to-net | 8.4% | the full year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KNSA
this stock
Kiniksa Pharmaceuticals International, plc
|
$11.98B | +86.1% | +60.1% | 84.3 | 2.8% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$64.91B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$56.30B | +13.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.49B | +2.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$42.85B | +17.8% | +4.3% | 60.3 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KNSA | +0.9% | +20.0% | +62.0% | +3.2% | +86.1% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +0.5% | +15.6% | +48.2% | -0.7% | +72.2% |
Key facts
CIK
1730430
CUSIP
G52694109
13F (30d)
257 filings
254 filers
Visit website
Investor relations